Adrenocortical Cancer in Carney Complex: A Paradigm of Endocrine Tumor Progression or an Association of Genetic Predisposing Factors?
Jérôme Bertherat
Institut National de la Santé et de la Recherche Médicale Unité 1016, Institut Cochin, Paris Descartes University, 75006 Paris, France; and Reference Center for Rare Adrenal Diseases, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, 75014 Paris, France
C arney complex (CNC) was described in 1985 as “the complex of myxomas, spotty pigmentation, and en- docrine overactivity” (1). The most frequent manifesta- tions of CNC are lentiginosis, myxomas, and ACTH-in- dependent Cushing’s syndrome due to primary pigmented nodular adrenocortical disease (PPNAD). PPNAD is a unique cause of adrenal Cushing syndrome in which bi- lateral pigmented micronodules are typically visible at macroscopic examination in the adrenal cortex. It is mostly the investigation of this rare type of adrenal tumors that led to the identification of CNC by Dr. J. A. Carney at the Mayo Clinic (2). Since the first description of CNC, an autosomal dominant inheritance was postulated. In 2000, the identification of the CNC1 gene (PRKAR1A), located at 17q22-24, was reported by Stratakis and col- leagues (3) at the National Institutes of Health. This gene encodes the regulatory subunit 1A of the protein kinase A, a central component of the cAMP signaling pathway. Be- cause cAMP signaling is activated by various molecular and cellular defects in endocrine tumors, it appeared quickly that the identification of CNC1 was a major step for the understanding of endocrine tumorigenesis. Germ- line PRKAR1A mutations are heterozygous inactivating mutations. Allelic loss of the wild-type allele is frequently observed in tumors from CNC patients. Therefore, PRKAR1A is considered as a tumor suppressor gene.
So far only PPNAD, which is a typical benign secreting tumor with a very slow growth, has been reported in ad- renal tumors of CNC patients. In this issue of the JCEM, two cases of adrenocortical cancer (ACC) are reported in CNC patients with germline PRKAR1A mutations. The
paper by Anselmo et al. (20) describes a large Azorean family with at least 10 CNC patients and a germline heterozygous PRKAR1A point mutation (S147G). The in- dex case was a 28-yr-old female who presented with a right 12-cm ACC with liver metastasis arising in the back- ground of bilateral PPNAD. Clinical and hormonal inves- tigations showed cortisol and androgen excess. Three other family members presented with PPNAD and a typ- ical paradoxical increased cortisol secretion after dexa- methasone suppression test. The other frequent CNC manifestation in this family was lentiginosis (facial pig- mented macules typically located on the lips and eyelids in CNC). The paper by Morin et al. (21) describes a 22-yr-old female with cardiac myxoma and lentiginosis. Her mother also suffered from cardiac myxoma at age 23 and had lentiginosis. A germline heterozygous PRKAR1A muta- tion that creates a premature stop codon in exon 2 of the gene (p.Lys32Argfs*12) was found in the index case. Mu- tant PRKAR1A mRNA with a premature stop codon are usually degraded by a mechanism of nonsense-mediated mRNA decay, inactivating the mutant allele. This applies to the majority (about 80%) of the PRKAR1A mutations that have been reported (4). This 22-yr-old female patient was diagnosed with a cortisol- and androgen-secreting 8.5-cm tumor of the left adrenal that was removed by laparoscopy. Pigmented micronodules typical of PPNAD were observed at pathological examination in the adrenal adjacent to the ACC. Three months after surgery, local recurrence was observed. The patient was then reoperated and treated with mitotane. Twenty-nine months later, liver and pulmonary metastasis were progressing.
Copyright @ 2012 by The Endocrine Society
doi: 10.1210/jc.2011-3327 Received December 9, 2011. Accepted January 5, 2012.
In these two cases, the clinical characteristics of the unilateral adrenocortical tumor that developed in the background of PPNAD are quite typical of ACC. The co- secretion of androgen and cortisol is observed in the ma- jority of secreting ACC (5), whereas benign secreting tu- mors cause cortisol excess only. The large size of the tumors is also suggestive of ACC. In both cases, the rapid occurrence of metastasis or local recurrence that was proven by pathological investigation to be of adrenal or- igin is demonstrative of the malignant nature of the adre- nal tumor. Because the adjacent adrenal cortex showed pigmented micronodules, it is clear that the ACC devel- oped in the background of PPNAD. This is compatible with a model of tumor progression from adrenal hyper- plasia to benign nodule, and then cancer. This multistep tumorigenesis is a general scheme usually accepted for co- lon cancer. Some rare cases of ACC that have apparently developed in the background of a benign tumor have been reported previously (6, 7). Considering that most adrenal incidentalomas are benign adenomas, the prevalence of adrenocortical adenomas might be higher than 1%, whereas the prevalence of ACC is estimated between 4 and 12 per million (8). Therefore, if this multistep progression was a general rule, the epidemiology tells us that the prob- ability of a benign adrenocortical lesion to acquire the full set of molecular alterations needed to become a malignant tumor would be very low.
The study of familial tumor syndromes responsible for ACC has been, before the genomic contemporary area, the most productive way to elucidate the molecular genetics of adrenocortical tumors (9). The study of the Li-Fraumeni syndrome due to germline mutations of the tumor sup- pressor gene TP53 led to the identification of somatic TP53 mutations in sporadic ACC. The study of the Beck- with-Wiedemann syndrome due to overexpression of the growth factor IGF-II led to the report of IGF-II overex- pression in sporadic ACC. However, in these two inher- ited neoplasia syndromes the characteristics of the ob- served adrenal tumors are quite homogenous, and the progression from a benign to a malignant tumor is usually not reported.
Is CNC a new example of a genetic syndrome that would help to elucidate the molecular genetics of ACC ? In these two CNC patients, it is tempting to speculate that the development of ACC was initiated by the inactivating mu- tation of PRKAR1A. Indeed, loss of heterozygosity (LOH) at the 17q22-24 PRKAR1A locus is frequent in ACC (10), but so far somatic PRKAR1A mutations have only been reported in secreting adrenocortical adenomas. In the ACC from the CNC patient from the Azores investigated by Stratakis and colleagues (20), no LOH at the PRKAR1A locus could be observed. However, the S147G
germline PRKAR1A mutation of this family belongs to the minority of mutations that give rise to an expressed mu- tant protein. These mutations are less often associated with LOH of the wild-type allele and might exert a dom- inant-negative effect (11). Interestingly, the expressed mu- tations are often associated with more severe forms of CNC, including malignant tumors (4, 12). Increased pro- tein kinase A activity was demonstrated for the S147G- expressed PRKAR1A mutant. This mutant stimulates phosphorylation of the transcription factor cAMP re- sponse element-binding protein. However, the decrease of this transcription factor, instead of its overactivation, has been reported in ACC (13).
In PPNAD, by contrast with the lack of previous report of ACC, benign macronodules (between 1 and 3.5 cm) have been described. When they are unilateral, they can even be misdiagnosed as unilateral adrenal adenomas be- fore the diagnosis of PPNAD or CNC (14). Molecular analysis of these macronodules can demonstrate the oc- currence of a somatic alteration, as ß-catenin (CTNNB1) or PRKAR1A-inactivating mutations (7, 14). The multi- step tumorigenesis model suggests that the occurrence of this somatic genetic defect restricted to the macrono- dule might participate in its development. Furthermore, ß-catenin mutations are found in ACC, and ß-catenin nu- clear accumulation, as shown by immunohistochemistry, is associated with more aggressive tumors (15). Interest- ingly, in the case reported by Anselmo et al. (20), a cyto- plasmic accumulation of ß-catenin is found, suggesting activation of the pathway.
An alternative hypothesis for the development of ACC in these two CNC patients would be the coexistence of additional germline factors predisposing to malignancies. We have previously shown that in CNC patients with PRKAR1A mutation, the development of PPNAD or tes- ticular tumors is associated with the presence of germline variants of the phosphodiesterase PDE11A4 (16). In this situation, the effect of the mutation of the causative gene PRKAR1A is potentiated by the variant of the second “modifyer” gene. In the patient reported by Morin et al. (21), a germline variant of the tumor suppressor gene TP53 was observed. This Pro72Arg variant has been pre- viously associated, as discussed by the authors, with var- ious malignancies. Transgenic mice heterozygous for inactivation of both PRKAR1A and TP53 [Prkar1a(+/-) Trp53(+/-)] develop more malignancies than the single heterozygous animals (17). They also present an in- creased susceptibility to develop chemically induced skin tumors. Hopefully, most tumors observed in pa- tients with PRKAR1A mutations are benign. This fits well with the concept that activation of the cAMP pathway is associated with the development of benign secreting en-
docrine tumors. However, it is possible that the associa- tion of PRKAR1A mutation with other genetic factors that play a role in the susceptibility to develop malignancy would stimulate cancer development. Interestingly, in the family reported by Anselmo et al. (20), several malignan- cies (lung adenocarcinoma, colon cancer, melanoma … ) have been observed in patients that were not all carriers of the PRKAR1A mutation. It is likely that predisposing ge- netic factors might participate in these malignancies and could also have been present in the CNC patient that de- veloped an ACC.
Now that we know the possibility of ACC development in CNC patients, what would be the recommendation for patient management? The rarity of CNC and ACC pre- cludes statistical demonstration of their association. Now one has to consider the association as plausible, regardless of the molecular explanation. CNC patients are routinely investigated for cortisol excess. Adrenal imaging is also done quite systematically, especially in the case of steroid excess. In an international series of 353 CNC patients, no ACC has been clearly reported, despite 212 of the patients having PPNAD (12). Since 2008, a prospective screening program of CNC patients is being done at the national level in France with systematic endocrine and imaging (computed tomography scan) investigations (www. ClinicalTrials.gov identifier: NCT00668291). To date, no ACC has been reported in the analysis of the first 68 en- rolled patients (J. Bertherat, personal communication). This reassures us that ACC is quite rare in CNC, even if it could be considered as part of the syndrome. However, one can speculate that early adrenal surgery in patients with PPNAD because of Cushing’s syndrome prevents the later development of the malignant tumor. For patient counseling, familial anamnesis of cancer might be impor- tant information on the basis of these two case reports. Because the two patients reported in this issue of the JCEM presented steroid excess, it is likely that the current advice of annual hormonal investigations for steroid excess would be sensitive enough to detect an ACC. When Cush- ing’s syndrome is demonstrated, adrenal imaging is done. Abdominal/adrenal imaging can also be done systemati- cally in CNC workup, but at present there is no clear recommendation on its frequency. In patients with a ma- cronodule larger than 3 to 4 cm, especially with androgen excess, one could discuss the diagnosis of ACC. In these patients, adrenal expert surgeons should take into consid- eration the debate over the use of open surgery vs. lapa- roscopy for small ACC (18, 19). This is important to con- sider because PPNAD is usually operated by laparoscopy.
Acknowledgments
Address all correspondence and requests for reprints to: Jerome Bertherat, M.D., Ph.D., Service d’endocrinologie Hopital Cochin 27, rue du Faubourg Saint-Jacques, 75014 Paris, France. E-mail: jerome.bertherat@cch.aphp.fr.
Disclosure Summary: The author has nothing to declare.
References
1. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL 1985 The complex of myxomas, spotty pigmentation, and endocrine overac- tivity. Medicine (Baltimore) 64:270-283
2. Carney JA, Young WF 1992 Primary pigmented nodular adreno- cortical disease and its associated conditions. Endocrinologist 2:6-21
3. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA 2000 Mutations of the gene en- coding the protein kinase A type I-a regulatory subunit in patients with the Carney complex. Nat Genet 26:89-92
4. Horvath A, Bertherat J, Groussin L, Guillaud-Bataille M, Tsang K, Cazabat L, Libé R, Remmers E, René-Corail F, Faucz FR, Clauser E, Calender A, Bertagna X, Carney JA, Stratakis CA 2010 Mutations and polymorphisms in the gene encoding regulatory subunit type 1-a of protein kinase A (PRKAR1A): an update. Hum Mutat 31:369- 379
5. Fassnacht M, Allolio B 2009 Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 23:273-289
6. Bernard MH, Sidhu S, Berger N, Peix JL, Marsh DJ, Robinson BG, Gaston V, Le Bouc Y, Gicquel C 2003 A case report in favor of a multistep adrenocortical tumorigenesis. J Clin Endocrinol Metab 88:998-1001
7. Gaujoux S, Tissier F, Groussin L, Libé R, Ragazzon B, Launay P, Audebourg A, Dousset B, Bertagna X, Bertherat J 2008 Wnt/B- catenin and cAMP/PKA signaling pathways alterations and somatic B-catenin gene mutations in the progression of adrenocortical tu- mors. J Clin Endocrinol Metab 93:4135-4140
8. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS 2003 Management of the clinically inapparent ad- renal mass (“incidentaloma”). Ann Intern Med 138:424-429
9. Libé R, Bertherat J 2005 Molecular genetics of adrenocortical tu- mours, from familial to sporadic diseases. Eur J Endocrinol 153: 477-487
10. Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergio- poulos S, Papageorgiou T, Bourdeau I, Kirschner LS, Vincent-De- jean C, Perlemoine K, Gicquel C, Bertagna X, Stratakis CA 2003 Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 63:5308-5319
11. Groussin L, Kirschner LS, Vincent-Dejean C, Perlemoine K, Jullian E, Delemer B, Zacharieva S, Pignatelli D, Carney JA, Luton JP, Bertagna X, Stratakis CA, Bertherat J 2002 Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory sub- unit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology. Am J Hum Genet 71:1433-1442
12. Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, Libe R, René-Corail F, Stergiopoulos S, Bourdeau I, Bei T, Clauser E, Calender A, Kirschner LS, Bertagna X, Carney JA, Stratakis CA 2009 Mutations in regulatory subunit type 1A of cyclic adenosine 5’-monophosphate-dependent protein kinase (PRKAR1A): pheno-
type analysis in 353 patients and 80 different genotypes. J Clin En- docrinol Metab 94:2085-2091
13. Groussin L, Massias JF, Bertagna X, Bertherat J 2000 Loss of ex- pression of the ubiquitous transcription factor cAMP response ele- ment-binding protein (CREB) and compensatory overexpression of the activator CREMt in the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 85:345-354
14. Groussin L, Jullian E, Perlemoine K, Louvel A, Leheup B, Luton JP, Bertagna X, Bertherat J 2002 Mutations of the PRKAR1A gene in Cushing’s syndrome due to sporadic primary pigmented nodular adrenocortical disease (PPNAD). J Clin Endocrinol Metab 87: 4324-4329
15. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libé R, Chokri I, Audebourg A, Royer B, Sbiera S, Vacher-Lavenu MC, Dousset B, Bertagna X, Allolio B, Bertherat J, Tissier F 2011 ß-Catenin activation is associated with specific clinical and patho- logic characteristics and a poor outcome in adrenocortical carci- noma. Clin Cancer Res 17:328-336
16. Libé R, Horvath A, Vezzosi D, Fratticci A, Coste J, Perlemoine K, Ragazzon B, Guillaud-Bataille M, Groussin L, Clauser E, Raffin- Sanson ML, Siegel J, Moran J, Drori-Herishanu L, Faucz FR, Lodish M, Nesterova M, Bertagna X, Bertherat J, Stratakis CA 2011 Fre- quent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as
a modifier of the phenotype. J Clin Endocrinol Metab 96:E208- E214
17. Almeida MQ, Muchow M, Boikos S, Bauer AJ, Griffin KJ, Tsang KM, Cheadle C, Watkins T, Wen F, Starost MF, Bossis I, Nesterova M, Stratakis CA 2010 Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. Hum Mol Genet 19:1387-1398
18. Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Do- herty GM 2010 Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg 34:1380-1385
19. Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hah- ner S, Fassnacht M 2010 Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 58:609-615
20. Anselmo J, Medeiros S, Carneiro V, Greene E, Levy I, Nesterova M, Lyssikatos C, Horvath A, Carney JA 2012 A large family with Car- ney complex caused by the S147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer. J Clin Endocrinol Metab 97:351-359
21. Morin E, Mete O, Wasserman J, Joshua AM, Asa SL 2012 Carney complex with adrenal cortical carcinoma. J Clin Endocrinol Metab 97:E202-E206
THE ENDOCRINE SOCIETY®
Save the Date for Endocrine Board Review Course, September 11-12, 2012, Miami, Florida. www.endo-society.org/CEU